A nationwide ban on conventional syringes, intended to curb Pakistan's escalating HIV crisis, has prompted an urgent plea from pediatric specialists warning that the policy could inadvertently endanger the lives of newborns and critically ill children. The Drug Regulatory Authority of Pakistan (Drap) moved to prohibit traditional syringes after a surge in HIV cases linked to unsafe medical practices, but the Pakistan Paediatric Association (PPA) argues that one size—specifically the 10cc syringe—cannot be eliminated without creating a clinical bottleneck in neonatal and pediatric wards. Main Developments Under Drap's phased ban, conventional 1cc (non-insulin) disposable syringes are prohibited from December 31, 2026, while retail and market sales of conventional 10cc disposable syringes face prohibition from January 1, 2027. The PPA, through a letter authored by Dr. Muhammad Khalid Shafi, has formally requested an exemption or targeted exclusion for 10cc syringes to protect pediatric and neonatal clinical operations. Dr. Shafi, who also chairs the National Immunisation Technical Advisory Group, emphasized that the 10cc syringe is an irreplaceable tool in neonatal intensive care units and pediatric wards. These syringes are used for accurate reconstitution and dilution of intravenous medications, enteral feeding through nasogastric and orogastric tubes in premature infants, and measuring oral liquid formulations for children who cannot swallow standard doses. Read also: AJK Employee Polling Postponed Amid Security Fears in Poonch, Sudhnoti Background The ban follows an alarming increase in pediatric HIV cases across Pakistan, which the PPA describes as an unprecedented surge linked to the reuse of contaminated syringes. Drap's regulatory action aims to eliminate the practice of syringe reuse by removing conventional syringes from the market, a move the authority considers essential for curbing blood-borne pathogen transmission. However, the PPA contends that the blanket prohibition fails to differentiate between syringes that are frequently reused in unsafe settings and those that are essential for clinical procedures where no viable alternative exists. The association notes that while the intent to reduce HIV transmission is commendable, the policy must be evidence-based and targeted to avoid unintended harm. Why It Matters If the ban proceeds without an exemption for 10cc syringes, pediatric and neonatal wards could face an immediate shortage of critical tools, jeopardizing daily life-saving interventions. The PPA warns that a regulatory measure designed to improve public health could inadvertently disrupt essential medical care for the most vulnerable patients—premature infants and critically ill children. Moreover, the controversy highlights a broader tension in public health policy: the need to balance infection control with maintaining access to indispensable medical equipment. Without a targeted approach, the ban risks creating a clinical vacuum that safer alternatives are not yet ready to fill. What's Next The PPA has called on Drap to convene a dedicated advisory panel including clinical experts, pediatric infectious disease specialists, and PPA representatives. This panel would review infection control strategies and establish evidence-based guidelines that target the true drivers of syringe reuse, rather than imposing a blanket prohibition. Until such a panel convenes and evaluates alternatives, the association urges an immediate exemption for 10cc syringes to ensure that pediatric care is not disrupted. The outcome of this appeal will determine whether Pakistan's fight against HIV can proceed without collateral damage to its youngest patients.